CL-SAR
LIVE

Serial Number

98415088

Owner

Soley Therapeutics, Inc.

Attorney

John L. Slafsky

Filing Date

Feb 21, 2024

Add to watchlist:

No watchlists yet
View on USPTO

CL-SAR Trademark

Serial Number: 98415088

CL-SAR is a trademark filed by Soley Therapeutics, Inc. on February 21, 2024. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Soley Therapeutics, Inc. (6 trademarks)

1 Corporate Drive
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

February 21, 2024

Registration Date

Not Registered

Published for Opposition

December 17, 2024

Goods & Services

downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; downloadable computer software, namely, software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; downloadable computer software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computerized simulations, virtual screening, and generative chemistry; downloadable computer software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; downloadable computer software for analyzing and generating insights from the sensing and response capabilities of cells; downloadable computer software for decoding cellular language; downloadable computer software for stain-free brightfield time-lapse imaging of cells

drug discovery services; research and development services in the field of pharmaceutical preparations; providing online non-downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; providing online non-downloadable computer software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; software as a service (SAAS) services featuring software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; providing an online non-downloadable computer software platform for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, featuring software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computerized simulations, virtual screening, and generative chemistry; software as a service (SAAS) services featuring software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computerized simulations, virtual screening, and generative chemistry; providing an online non-downloadable computer software platform for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; providing an online non-downloadable computer software platform for analyzing and generating insights from the sensing and response capabilities of cells; software as a service (SAAS) services featuring software for analyzing and generating insights from the sensing and response capabilities of cells; providing online non-downloadable computer software for decoding cellular language; software as a service (SAAS) services featuring software for decoding cellular language; providing online non-downloadable computer software for stain-free brightfield time-lapse imaging of cells; software as a service (SAAS) services featuring software for stain-free brightfield time-lapse imaging of cells; preclinical drug discovery services used for identifying, designing, and optimizing chemical compounds; pharmaceutical product evaluation and preclinical evaluation of chemical series and chemical compounds in drug discovery via software using artificial intelligence; preclinical pharmaceutical drug development services used for identifying, designing, and optimizing chemical compounds; pharmaceutical drug development and discovery services, namely, identifying, designing, optimizing, and developing chemical series and chemical compounds via software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computational modeling, high-throughput screening, medicinal chemistry, biology, pharmacology, computerized simulations, virtual screening, and generative chemistry; providing an online searchable database in the fields of pharmaceuticals for scientific research purposes, in particular, pharmaceutical research and development, scientific research and development of pharmaceutical preparations, scientific development of new uses for pharmaceutical compounds, and scientific technical research; scientific research and development for scientific purposes, namely forecasting the use of molecules as drug compounds and developing new uses for pharmaceutical compounds; research and development in the field of drug discovery and development, molecular screening, cellular screening, phenomics, genetics, genomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; drug discovery services, namely, phenotypic screening services for discovering novel molecules to develop into drug compounds

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 17, 2026 EXRA
SOU EXTENSION 3 GRANTED
May 15, 2026 EX3G
SOU EXTENSION 3 FILED
May 15, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
May 15, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 24, 2025 EXRA
SOU EXTENSION 2 GRANTED
Dec 23, 2025 EX2G
SOU EXTENSION 2 FILED
Dec 23, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 23, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 27, 2025 EXRA
SOU EXTENSION 1 GRANTED
Feb 26, 2025 EX1G
SOU EXTENSION 1 FILED
Feb 26, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 26, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 17, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 17, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 11, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 16, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 14, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 14, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 14, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 17, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 17, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 17, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 11, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 27, 2024 NWOS
NEW APPLICATION ENTERED
Feb 21, 2024 NWAP